1. Zisapel N, inventor; Neurim Pharmaceuticals Ltd., assignee. Method and pharmaceutical formulation for treating benign prostatic hyperplasia. US patent 5,750,557. May 12, 1998. Column 10, lines 21-25. 2. Lee B-J, Parrott KA, Ayres JW, Sack RL. Design and evaluation of an oral controlled release delivery system for melatonin in human subjects. Int J Pharm. 1995;124(1):119-127. 3. Gooneratne NS, Edwards AY, Zhou C, Cuellar N, Grandner MA, Barrett JS. Melatonin pharmacokinetics following two different oral surge-sustained release doses in older adults. J Pineal Res. 2012;52(4):437-445. 4. Proietti S, Carlomagno G, Dinicola S, Bizzarri M. Soft gel capsules improve melatonin’s bioavailability in humans. Expert Opin Drug Metab Toxicol. 2014;10(9):1193-1198. 5. Aldhous M, Franey C, Wright J, Arendt J. Plasma concentrations of melatonin in man following oral absorption of different preparations. Br J Clin Pharmacol. 1985;19(4):517-521. 6. Zisapel N, inventor; Neurim Pharmaceuticals Ltd., assignee. United States Patent Application Publication: Methods for treating patients suffering from drug dependencies which lead to plasma melatonin deficiencies. Pub. No. US 2003/0040539. February 27, 2003.
David C. Brodner, MD, Senior Medical Advisor, Physician’s Seal, LLC Syed M. Shah, PhD, Scientific Advisor, Physician’s Seal, LLC